Shots:

• Pacira Signs a definitive agreement to acquire Flexion for $8.50/share in cash along with one non-tradeable CVR of ~$8.00/share in cash upon the achievement of sales & regulatory milestones. The transaction is expected to close in Q4’21
• The acquisition will support Pacira to expand its leadership position in non-opioid pain management with the addition of Flexion’s Zilretta
• Flexion’s Zilretta is the first FDA-approved treatment for OA knee pain utilizing ER microsphere technology

  | Ref: Globe Newswire | Image: Mass Bio